| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cutaneous squamous cell carcinoma, n (%) | 4 (5.7) | 3 (4.3) | .64 |
| Pancreatic adenocarcinoma, n (%) | 0 (0) | 3 (4.3) | .08 |
| Bronchial adenocarcinoma, n (%) | 1 (1.4) | 1 (1.4) | .98 |
| Prostatic adenocarcinoma, n (%) | 0 | 1 (1.4) | .39 |
| Colonic adenocarcinoma, n (%) | 1 (1.4) | 0 | .43 |
| Bladder cancer, n (%) | 0 | 1 (1.4) | .39 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| Kaposi sarcoma, (%) | 1 (1.4) | 0 | .43 |
| Noncutaneaous cancer, n (%) | 4 (5.7) | 6 (8.7) | .49 |
| Total cancer, n (%) | 8 (11.4) | 9 (13.0) | .59 |
| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cutaneous squamous cell carcinoma, n (%) | 4 (5.7) | 3 (4.3) | .64 |
| Pancreatic adenocarcinoma, n (%) | 0 (0) | 3 (4.3) | .08 |
| Bronchial adenocarcinoma, n (%) | 1 (1.4) | 1 (1.4) | .98 |
| Prostatic adenocarcinoma, n (%) | 0 | 1 (1.4) | .39 |
| Colonic adenocarcinoma, n (%) | 1 (1.4) | 0 | .43 |
| Bladder cancer, n (%) | 0 | 1 (1.4) | .39 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| Kaposi sarcoma, (%) | 1 (1.4) | 0 | .43 |
| Noncutaneaous cancer, n (%) | 4 (5.7) | 6 (8.7) | .49 |
| Total cancer, n (%) | 8 (11.4) | 9 (13.0) | .59 |
PTLD: posttransplant lymphoproliferative disease.
| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cutaneous squamous cell carcinoma, n (%) | 4 (5.7) | 3 (4.3) | .64 |
| Pancreatic adenocarcinoma, n (%) | 0 (0) | 3 (4.3) | .08 |
| Bronchial adenocarcinoma, n (%) | 1 (1.4) | 1 (1.4) | .98 |
| Prostatic adenocarcinoma, n (%) | 0 | 1 (1.4) | .39 |
| Colonic adenocarcinoma, n (%) | 1 (1.4) | 0 | .43 |
| Bladder cancer, n (%) | 0 | 1 (1.4) | .39 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| Kaposi sarcoma, (%) | 1 (1.4) | 0 | .43 |
| Noncutaneaous cancer, n (%) | 4 (5.7) | 6 (8.7) | .49 |
| Total cancer, n (%) | 8 (11.4) | 9 (13.0) | .59 |
| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cutaneous squamous cell carcinoma, n (%) | 4 (5.7) | 3 (4.3) | .64 |
| Pancreatic adenocarcinoma, n (%) | 0 (0) | 3 (4.3) | .08 |
| Bronchial adenocarcinoma, n (%) | 1 (1.4) | 1 (1.4) | .98 |
| Prostatic adenocarcinoma, n (%) | 0 | 1 (1.4) | .39 |
| Colonic adenocarcinoma, n (%) | 1 (1.4) | 0 | .43 |
| Bladder cancer, n (%) | 0 | 1 (1.4) | .39 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| Kaposi sarcoma, (%) | 1 (1.4) | 0 | .43 |
| Noncutaneaous cancer, n (%) | 4 (5.7) | 6 (8.7) | .49 |
| Total cancer, n (%) | 8 (11.4) | 9 (13.0) | .59 |
PTLD: posttransplant lymphoproliferative disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
